Segment (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Summary of Reconciles Reported Revenues to Net (Loss) Income under Significant Expense Principle

The following table reconciles reported revenues to net (loss) income under the significant expense principle for the years ended December 31, 2024 and 2023 (in thousands):

	For the year ended December 31,
	2024			2023
Research and Development Expenses:
RAP-219 program external expenses	$	22,080		$	10,202
Preclinical programs external expenses		16,535			6,335
R&D personnel-related costs (including stock-based    compensation)		19,500			9,939
Other costs		2,820			1,523
General and Administrative Expenses:
G&A personnel-related costs (including stock-based    compensation)		13,989			4,324
Professional and consulting costs		5,482			3,158
Facility related and other		2,649			698
Loss from operations	$	(83,055	)	$	(36,179	)
Interest income		12,138			2,527
Change in fair value of preferred stock tranche right liability		(7,390	)		(1,124	)
Net loss before income taxes		(78,307	)		(34,776	)
Provision for income taxes		—			10
Net loss	$	(78,307	)	$	(34,786	)